Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 307-301-9 | CAS number: 97593-01-6
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 02 December 2014 - 30 November 2015
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Study conducted according to the OECD 408 guideline and GLP compliance. Fully adequate for assessment.
- Justification for type of information:
- A discussion and report on the read across strategy is given as an attachment in Section 13.
Cross-referenceopen allclose all
- Reason / purpose for cross-reference:
- read-across: supporting information
Reference
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- read-across based on grouping of substances (category approach)
- Adequacy of study:
- key study
- Study period:
- 02 December 2014 - 30 November 2015
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Study conducted according to the OECD 408 guideline and GLP compliance. Fully adequate for assessment.
- Justification for type of information:
- A discussion and report on the read across strategy is given as an attachment in Section 13.
- Reason / purpose for cross-reference:
- read-across source
- Reason / purpose for cross-reference:
- other: Independent analysis
- Reason / purpose for cross-reference:
- other: GLP Certificate
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- Qualifier:
- according to guideline
- Guideline:
- other: Commission Regulation (EC) No 440/2008 of 30 May 2008, laying down test methods pursuant to Regulation (EC) No 1907/2006 of the European Parliament and of the Council on the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH).
- GLP compliance:
- yes (incl. QA statement)
- Specific details on test material used for the study:
- - Test Material : Octadecene
- CAS 27070-58-2
- Chemical name: C18 Isomerized Olefin
– Physical State/Appearance : Clear colourless liquid
- Purity : 94.1%- Label : C18 Isomerised Olefin Lot 747273
– Batch Number : 747273- Date Received : 03 March 2014
- Storage Conditions : Ambient temperature, in the dark and under nitrogen
- Expiry Date : 10 Feb 2016
Octadecene used in this study was a typical production sample, according to the details included in the boundary composition in IUCLID section 1.2. Octadecene was chosen in the Higher Olefins category testing strategy because it represents a substance with high di-sub content (category range 0.3 – 94%) and high tri-sub content (category range 1 - 65%). Please see the testing strategy attached in section 13 for further details. - Species:
- rat
- Strain:
- other: Wistar Han™:RccHan™:WIST
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Harlan Laboratories U.K. Ltd., Oxon, UK
- Age at study initiation: six to eight weeks old
- Weight at study initiation: Males: 200 to 232g, Females: 141 to 175g
- Housing: The animals were housed in groups of three or four by sex in solid floor polypropylene cages with stainless steel mesh lids and softwood flake bedding
- Diet (e.g. ad libitum): A pelleted diet (Rodent 2014C Teklad Global Certified Diet, Harlan Laboratories U.K. Ltd., Oxon, UK - free access
- Water (e.g. ad libitum): free access
- Acclimation period: 9 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 3 °C
- Humidity (%): 50 ± 20%
- Air changes (per hr): 15
- Photoperiod (hrs dark / hrs light): 12 hr light/12 hr dark - Route of administration:
- oral: gavage
- Vehicle:
- other: arachis oil BP
- Details on oral exposure:
- The test item was administered daily, for ninety consecutive days, by gavage using a stainless steel cannula attached to a disposable plastic syringe. Control animals were treated in an identical manner with 4 mL/kg of Arachis oil BP.
The volume of test and control item administered to each animal was based on the most recent
scheduled body weight and was adjusted at weekly intervals. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The test item was prepared in Arachis oil BP solution. The stability and homogeneity of the test item formulations were determined by Harlan Laboratories Ltd., Shardlow, UK, Analytical Services. The results of the analytical determination showed that the formulations were stable for at least 18 days. Formulations were prepared and stored at approximately 4 °C in the dark.
The results indicate that the prepared formulations were within 90% to 102% of the nominal concentration confirming the suitability and accuracy of the formulation procedure. - Duration of treatment / exposure:
- 90 days
- Frequency of treatment:
- daily
- Remarks:
- Doses / Concentrations:
0 mg/kg bw/day
Basis:
actual ingested - Remarks:
- Doses / Concentrations:
100 mg/kg bw/day
Basis:
actual ingested - Remarks:
- Doses / Concentrations:
300 mg/kg bw/day
Basis:
actual ingested - Remarks:
- Doses / Concentrations:
1000 mg/kg bw/day
Basis:
actual ingested - No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: The dose levels were selected based on a fourteen day dose range finding study in the rat (Harlan Study Number: 41403655). In this study, a high dosage of 1000 mg/kg bw/day was well tolerated, therefore, the dose levels 0 (Control), 100, 300 and 1000 mg/kg bw/day were selected for the OECD 408 study.
- The test item was administered daily, for ninety consecutive days, by gavage using a stainless steel cannula attached to a disposable plastic syringe. - Control animals were treated in an identical manner with 4 mL/kg of Arachis oil BP. - Observations and examinations performed and frequency:
- Clinical Observations:
- Signs of toxicity
- Ill-health or behavioural change immediately before dosing
Functional Observations:
- Prior to the start of treatment and at weekly intervals thereafter
Behavioural Assessment
- Functional Performance Tests: Motor Activity, Forelimb/Hindlimb Grip Strength
- Sensory Reactivity
Body Weight
- Individual body weights were recorded on Day 1 (prior to dosing), at weekly intervals thereafter and at terminal kill
Food Consumption
- Weekly intervals throughout the study
Water Consumption
- Daily by visual inspection of the water bottles
Ophthalmoscopic Examination
- Pre-treatment and before termination of treatment (during Week 12)
Laboratory Investigations
- End of the study
- Haematology
- Blood Chemistry - Sacrifice and pathology:
- Sacrifice: All animals were terminated by intravenous overdose of a suitable barbiturate agent followed by exsanguination.
Pathology
- Necropsy: all animals were subjected to a full external and internal examination.
- Organ Weights (Adrenals, Ovaries, Brain Spleen, Epididymides, Testes, Heart, Thymus, Kidneys, Uterus, Liver)
- Histopathology: Samples of selected tissues were removed from all animals and preserved.
- Tissues from all control and high dose group animals were examined microscopically. - Statistics:
- Where considered appropriate, quantitative data was subjected to statistical analysis to detect the significance of intergroup differences from control; statistical significance was achieved at a level of p<0.05. Statistical analysis was performed on the following parameters:
Grip Strength, Motor Activity, Body Weight Change, Hematology, Blood Chemistry, Absolute Organ Weights, Body Weight-Relative Organ Weights.
Data were analyzed using the decision tree from the Provantis TM Tables and Statistics Module as detailed as follows:
Where appropriate, data transformations were performed using the most suitable method. The homogeneity of variance from mean values was analyzed using Bartlett’s test. Intergroup variances were assessed using suitable ANOVA, or if required, ANCOVA with appropriate
covariates. Any transformed data were analyzed to find the lowest treatment level that showed a significant effect using the Williams Test for parametric data or the Shirley Test for nonparametric data.
If no dose response was found but the data shows non-homogeneity of means, the data were analysed by a stepwise Dunnett’s (parametric) or Steel (non-parametric) test to determine significant difference from the control group. Where the data were unsuitable for these analyses, pair-wise tests was performed using the Student t-test (parametric) or the MannWhitney U test (non-parametric). Probability values (p) are presented as follows:
p<0.01 **
p<0.05 *
p>0.05 (not significant)
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Treatment at 1000 mg/kg bw/day was associated with increased post-dosing salivation for both sexes. Similar increased post-dosing salivation was also observed for one male and four females at 300 mg/kg bw/day.
- Mortality:
- no mortality observed
- Description (incidence):
- There were no unscheduled deaths on the study.
- Body weight and weight changes:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There was no effect of treatment on body weight performance for either sex at 100, 300 or 1000 mg/kg bw/day.
Overall body weight gain for treated animals was slightly superior to control and the occasional statistically significant differences in body weight gain for treated animals were considered to reflect normal biological variation and were unrelated to treatment. - Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- There was no effect of treatment on food consumption for either sex at 100, 300 or 1000 mg/kg bw/day.
- Food efficiency:
- no effects observed
- Description (incidence and severity):
- There was no effect of treatment on food conversion efficiency for either sex at 100, 300 or 1000 mg/kg bw/day.
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Description (incidence and severity):
- There was no effect of treatment on water consumption for either sex at dosages of 100, 300 or 1000 mg/kg bw/day.
- Ophthalmological findings:
- no effects observed
- Description (incidence and severity):
- Ophthalmic examination of the eyes from rats receiving 1000 mg/kg bw/day did not indicate any effect of treatment.
- Haematological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There was considered to be no effect of treatment on hematology parameters for either sex at 100, 300 or 1000 mg/kg bw/day.
At all dosages, mean corpuscular hemoglobin concentration for both sexes was lower than control; with the exception of females at 100 mg/kg bw/day, all differences from control attained statistical significance. However, only individual values for two males at 100 mg/kg bw/day and one male at 300 mg/kg bw/day exceeded the historical control range, while this historical range was exceeded by the majority of control males. For females only one control female exceeded the historical control range and all individual values for treated females were within the historical control range.
For females at 1000 mg/kg bw/day, mean hemoglobin level were also statistically significantly lower than control; however only one individual value for these treated animals was below the historical control range while this historical range was exceeded by four control females. - Clinical biochemistry findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There was considered to be no effect of treatment on blood chemistry parameters for either sex at 100, 300 or 1000 mg/kg bw/day.
For males at 1000 mg/kg bw/day, higher albumin and calcium levels attained statistical significance when compared with control but all individual values were within the historical control range; additionally for albumin there was no accompanying statistically significant difference from control for total protein or albumin/globulin ratio. Lower bile acid levels for males at this dosage also attained statistical significance when compared with control. While
individual values for half of these treated animals exceeded the control range, the majority of control values also exceeded this historical range. These differences from control in blood parameters, in the absence of any histopathological correlates were considered to be incidental and unrelated to treatment.
Additionally, for females at 1000 mg/kg bw/day, lower urea and creatinine levels also attained statistical significance when compared with control but all individual values for treated animals were within the historical control range while approximately half of the control urea values exceeded this historical range. For females at all dosage levels, lower bile acid values attained statistical significance when compared to controls but there was no dose response relationship.
Higher inorganic phosphorus levels for females at 300 mg/kg bw/day and lower glucose levels for females at 100 mg/kg bw/day also attained statistical significance when compared with control but there were no similar findings at the high dosage of 1000 mg/kg bw/day.
Overall these differences in urea, bile acid, creatinine and glucose levels were considered to be incidental and unrelated to treatment. - Urinalysis findings:
- not examined
- Behaviour (functional findings):
- effects observed, non-treatment-related
- Description (incidence and severity):
- Behavioral Assessments:
Weekly assessment of the animals in a standard arena did not reveal any obvious adverse effects of treatment at dosages of 100, 300 or 1000 mg/kg bw/day.
Functional Performance Tests:
Assessment of functional performance using grip strength and motor activity did not indicate any obvious effects of treatment for either at dosages of 100, 300 or 1000 mg/kg bw/day.
For males, higher values for hind limb grip strength during the third testing occasion attained statistical significance at all dosages, when compared with controls. Additionally, fore limb grip strength for males at 300 mg/kg bw/day was also statistically significantly higher than control during the first testing occasion. Given the lack of any dosage relationship, these observed differences in performance from control were considered to reflect normal biological variation and were unrelated to treatment.
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- There were no statistically significant differences from control in absolute and body weight relative organ weights for either sex at 100, 300 or 1000 mg/kg bw/day.
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- Neither the type, incidence nor distribution of findings observed at terminal necropsy indicated any obvious effect of treatment 100, 300 or 1000 mg/kg bw/day.
- Neuropathological findings:
- not specified
- Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- Neither the type, incidence nor distribution of findings observed during microscopic examination of the tissues from animals that received 1000 mg/kg bw/day indicated any effect of treatment.
- Histopathological findings: neoplastic:
- not specified
- Other effects:
- not specified
- Details on results:
- Mortality
- No unscheduled death
Clinical Observations
- 1000 mg/kg bw/day: male and female rats showed increased salivation.
- 300 mg/kg bw/day: Increased salivation was observed in one male and four females. This effect is not considered related to the treatment.
- 100 mg/kg bw/day: no effects
Functional Observations
- Hind limb grip strength fore limb grip strength were observed in males treated with 300 mg/kg bw/day. The lack of dose-response relationship suggested
that these observations reflected normal biological variation and were unrelated to treatment.
- No treatment-related effects were observed in the behavioural and sensory reactivity parameters.
Body Weight
- There was no effect of treatment on body weight performance for either sex at 100, 300 or 1000 mg/kg bw/day.
Overall body weight gain for treated animals was slightly superior to control and the occasional statistically significant differences in body weight gain for treatedanimals were considered to reflect normal biological variation and were unrelated to treatment.
Food Consumption
- There was no effect of treatment on food consumption for either sex at 100, 300 or 1000 mg/kg bw/day.
Water Consumption
- There was no effect of treatment on water consumption for either sex at dosages of 100, 300 or 1000 mg/kg bw/day.
Ophthalmoscopic Examination
- Ophthalmic examination of the eyes from rats receiving 1000 mg/kg bw/day did not indicate any effect of treatment.
Haematological findings
-There was considered to be no effect of treatment on hematology parameters for either sex at 100, 300 or 1000 mg/kg bw/day.
Blood Chemistry
- There was considered to be no effect of treatment on blood chemistry parameters for either sex at 100, 300 or 1000 mg/kg bw/day.
Pathology
Necropsy and Histopatology
- Neither the type, incidence nor distribution of findings observed during microscopic examination of the tissues from animals that received 1000 mg/kg bw/day indicated any effect of treatment.
Organ Weights
- There were no statistically significant differences from control in absolute and body weight relative organ weights for either sex at 100, 300 or 1000 mg/kg bw/day. - Dose descriptor:
- NOEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No significant effects observed at 1000 mg/kg/day
- Critical effects observed:
- not specified
- Conclusions:
- Based on the results of this study, the No Observed Effect Level (NOEL) for systemic toxicity was considered to be 1000 mg/kg bw/day.
- Executive summary:
The daily oral gavage administration of Octadecene CAS 27070-58-2 to rats for a period of ninety consecutive days at dosages of 100, 300 or 1000 mg/kg bw/day was well tolerated and was not associated with any obvious signs of systemic toxicity for animals of either sex. At 1000 mg/kg bw/day and, to a much lesser extent, 300 mg/kg bw/day, treatment was associated with increased post-dosing salivation for both sexes but this was considered to reflect distaste or slight irritancy of the dosing formulations rather than any systemic effect of treatment. There were no effects of treatment indicated by body weight performance, food and water consumption, food conversion efficiency, functional observations or ophthalmic examinations.
Intergroup differences for hematology and blood chemistry parameters did not indicate any clear effect of treatment and the few mean values that attained statistical significance when compared with control were considered to be incidental and of no toxicological significance. There were no statistically significant differences apparent for organ weights and neither macroscopic nor subsequent microscopic examination of tissues revealed any treatment related effects.
Based on the results of this study, the No Observed Effect Level (NOEL) for systemic toxicity was considered to be 1000 mg/kg bw/day.
Table 1. Group Mean Functional Performance Test Values |
|||||
Group |
|
Males |
Females |
||
Overall Activity |
Test 3 Hindlimb (g) |
Overall Activity |
Test 3 Hindlimb (g) |
||
Group 1 (0 – Control) |
Mean |
918.0 |
255.9 |
1062.2 |
323.9 |
S.D. |
284.8 |
45.3 |
264.3 |
81.5 |
|
N |
10 |
10 |
10 |
10 |
|
|
|||||
Group 2 (100 mg/Kg bw/day) |
Mean |
768.7 |
465.0 ** |
939.7 |
292.0 |
S.D. |
206.2 |
151.6 |
309.7 |
102.0 |
|
N |
10 |
10 |
10 |
10 |
|
|
|||||
Group 3 (300 mg/Kg bw/day) |
Mean |
943.9 |
495.3 ** |
975.0 |
278.3 |
S.D. |
335.0 |
166.8 |
255.0 |
108.6 |
|
N |
10 |
10 |
10 |
10 |
|
|
|||||
Group 4 (1000 mg/Kg bw/day) |
Mean |
808.1 |
313.7** |
1045.6 |
400.5 |
S.D. |
306.2 |
106.8 |
240.4 |
176.5 |
|
N |
10 |
10 |
10 |
10 |
|
General Footnote: Unit = Time (seconds) for Motor Activity Assessments
* Significantly different from control group p<0.05
** Significantly different from control group p<0.01
Table 2. Group Mean Hematological Values - Males |
|||
Group |
|
Hb (g/dL) |
MCHC (g/dL) |
Group 1 (0 – Control) |
Mean |
16.17 |
34.60 |
S.D. |
0.89 |
0.65 |
|
N |
10 |
10 |
|
|
|||
Group 2 (100 mg/Kg bw/day) |
Mean |
16.57 |
34.09* |
S.D. |
0.57 |
0.59 |
|
N |
10 |
10 |
|
|
|||
Group 3 (300 mg/Kg bw/day) |
Mean |
16.32 |
34.01* |
S.D. |
0.73 |
0.58 |
|
N |
10 |
10 |
|
|
|||
Group 4 (1000 mg/Kg bw/day) |
Mean |
16.30 |
33.56** |
S.D. |
0.61 |
0.39 |
|
N |
10 |
10 |
|
* Significantly different from control group p<0.05
** Significantly different from control group p<0.01
Table 3. Group Mean Blood Chemical Values - Males |
|
|||
Group |
|
Albumin (g/dL) |
Ca++ mmol/l |
Bile Acid µmol/l |
Group 1 (0 – Control) |
Mean |
3.76 |
2.680 |
21.16 |
S.D. |
0.24 |
0.083 |
10.50 |
|
N |
10 |
10 |
10 |
|
|
|
|||
Group 2 (100 mg/Kg bw/day) |
Mean |
3.93 |
2.720 |
14.40 |
S.D. |
0.18 |
0.149 |
9.37 |
|
N |
10 |
10 |
10 |
|
|
|
|||
Group 3 (300 mg/Kg bw/day) |
Mean |
3.86 |
2.731 |
15.22 |
S.D. |
0.21 |
0.115 |
9.42 |
|
N |
10 |
10 |
10 |
|
|
|
|||
Group 4 (1000 mg/Kg bw/day) |
Mean |
3.97* |
2.801* |
12.26* |
S.D. |
0.13 |
0.080 |
7.91 |
|
N |
10 |
10 |
10 |
|
* Significantly different from control group p<0.05
Table 4. Group Mean Hematological Values - Females |
|||
Group |
|
Hb (g/dL) |
MCHC (g/dL) |
Group 1 (0 – Control) |
Mean |
16.13 |
34.37 |
S.D. |
0.68 |
0.81 |
|
N |
10 |
10 |
|
|
|||
Group 2 (100 mg/Kg bw/day) |
Mean |
15.94 |
34.16 |
S.D. |
0.54 |
0.27 |
|
N |
10 |
10 |
|
|
|||
Group 3 (300 mg/Kg bw/day) |
Mean |
16.14 |
33.97* |
S.D. |
0.93 |
0.30 |
|
N |
10 |
10 |
|
|
|||
Group 4 (1000 mg/Kg bw/day) |
Mean |
14.94** |
33.89* |
S.D. |
1.42 |
0.34 |
|
N |
10 |
10 |
|
* Significantly different from control group p<0.05
** Significantly different from control group p<0.01
Table 5. Group Mean Blood Chemical Values - Females |
|
|
|
|
|||
Group |
|
Urea mg/dl |
Glucose mg/dl |
P mmol/l |
ALAT IU/l |
Creat mg/dl |
Bile Acid µmol/l |
Group 1 (0 – Control) |
Mean |
49.4 |
183.4 |
1.62 |
55.8 |
0.892 |
36.18 |
S.D. |
8.9 |
30.6 |
0.35 |
10.3 |
0.134 |
19.69 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
|
|
|
|
|
|
|||
Group 2 (100 mg/Kg bw/day) |
Mean |
47.6 |
152.2** |
1.55 |
63.5 |
0.852 |
15.20* |
S.D. |
7.8 |
14.4 |
0.27 |
21.6 |
0.071 |
14.89 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
|
|
|
|
|
|
|||
Group 3 (300 mg/Kg bw/day) |
Mean |
45.1 |
169.5 |
1.96* |
59.2 |
0.894 |
25.32* |
S.D. |
12.0 |
16.1 |
0.31 |
19.4 |
0.238 |
18.37 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
|
|
|
|
|
|
|||
Group 4 (1000 mg/Kg bw/day) |
Mean |
40.4* |
170.5 |
1.56 |
73.7* |
0.795* |
17.72* |
S.D. |
5.5 |
18.6 |
0.28 |
14.5 |
0.048 |
13.51 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
|
Table 6. Group Mean Organ Weights with Corresponding Relative (% of Body Weight) Organ Weights |
|||||||||
|
|
Males |
Females |
||||||
0 Control |
100 mg/Kg bw/day |
300 mg/Kg bw/day |
1000 mg/Kg bw/day |
0 Control |
100 mg/Kg bw/day |
300 mg/Kg bw/day |
1000 mg/Kg bw/day |
||
Kidneys |
Mean (g) |
2.12673 |
2.19061 |
2.26685 |
2.20039 |
1.40115 |
1.50356 |
1.42171 |
1.52647 |
S.D. |
0.38474 |
0.23642 |
0.28298 |
0.28953 |
0.14245 |
0.08800 |
0.10481 |
0.14570 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
|
|
|||||||||
Mean (%) |
0.541 |
0.520 |
0.558 |
0.528 |
0.578 |
0.604 |
0.569 |
0.615 |
|
S.D. |
0.047 |
0.039 |
0.047 |
0.033 |
0.045 |
0.028 |
0.034 |
0.042 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
|
|
|||||||||
Liver |
Mean (g) |
12.6118 |
13.6667 |
13.6800 |
13.0910 |
8.20024 |
8.40268 |
8.26177 |
8.60674 |
S.D. |
2.28005 |
1.53962 |
1.78418 |
2.96040 |
0.88450 |
0.86053 |
0.59297 |
1.01931 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
|
|
|||||||||
Mean (%) |
3.207 |
3.239 |
3.357 |
3.113 |
3.382 |
3.370 |
3.306 |
3.463 |
|
S.D. |
0.261 |
0.176 |
0.219 |
0.286 |
0.258 |
0.292 |
0.201 |
0.267 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
|
|
|||||||||
Spleen |
Mean (g) |
0.69673 |
0.80295 |
0.72930 |
0.76011 |
0.53533 |
0.57430 |
0.57771 |
0.61159 |
S.D. |
0.10764 |
0.10653 |
0.09619 |
0.13641 |
0.05239 |
0.06556 |
0.12066 |
0.14834 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
|
|
|||||||||
Mean (%) |
0.178 |
0.191 |
0.179 |
0.182 |
0.221 |
0.230 |
0.232 |
0.247 |
|
S.D. |
0.023 |
0.024 |
0.016 |
0.017 |
0.020 |
0.025 |
0.053 |
0.063 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
|
* Significantly different from control group p<0.05
** Significantly different from control group p<0.01
Table 7. Summary Incidence of Necropsy Findings - Males |
||||
|
Males |
|||
0 Control |
100 mg/Kg bw/day |
300 mg/Kg bw/day |
1000 mg/Kg bw/day |
|
Number of animals examined |
10 |
10 |
10 |
10 |
Adrenals |
|
|||
Submitted |
(10) |
(10) |
(10) |
(10) |
No Visible Lesions |
10 |
10 |
10 |
9 |
Damaged On Removal; right |
0 |
0 |
0 |
1 |
|
||||
Kidneys |
|
|||
Submitted |
(10) |
(10) |
(10) |
(10) |
No Visible Lesions |
10 |
9 |
10 |
10 |
Increased Pelvic Space; right |
0 |
1 |
0 |
0 |
Fluid Filled; right |
0 |
1 |
0 |
0 |
|
||||
Lungs (With Bronchi) |
|
|||
Submitted |
(10) |
(10) |
(10) |
(10) |
No Visible Lesions |
9 |
10 |
10 |
8 |
Discolouration; Red |
1 |
0 |
0 |
2 |
Table 8. Summary Incidence of Necropsy Findings - Females |
||||
|
Females |
|||
0 Control |
100 mg/Kg bw/day |
300 mg/Kg bw/day |
1000 mg/Kg bw/day |
|
Number of animals examined |
10 |
10 |
10 |
10 |
Brain (Including Cerebrum, Cerebellum And Pons) |
|
|||
Submitted |
(10) |
(10) |
(10) |
(10) |
No Visible Lesions |
9 |
10 |
10 |
10 |
Damaged On Removal; right |
1 |
0 |
0 |
0 |
|
||||
Lungs (With Bronchi) |
|
|||
Submitted |
(10) |
(10) |
(10) |
(10) |
No Visible Lesions |
6 |
9 |
9 |
9 |
Discolouration; red |
4 |
1 |
1 |
1 |
|
||||
Uterus (With Cervix) |
|
|||
Submitted |
(10) |
(10) |
(10) |
(10) |
No Visible Lesions |
10 |
10 |
9 |
10 |
Discolouration; Red |
0 |
0 |
1 |
0 |
- Reason / purpose for cross-reference:
- other: Independent analysis
- Reason / purpose for cross-reference:
- other: GLP Certificate
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 015
- Report date:
- 2015
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- Qualifier:
- according to guideline
- Guideline:
- other: Commission Regulation (EC) No 440/2008 of 30 May 2008, laying down test methods pursuant to Regulation (EC) No 1907/2006 of the European Parliament and of the Council on the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH).
- GLP compliance:
- yes (incl. QA statement)
Test material
- Reference substance name:
- Octadecene
- EC Number:
- 248-205-6
- EC Name:
- Octadecene
- Cas Number:
- 27070-58-2
- Molecular formula:
- C18H36
- IUPAC Name:
- octadecene
- Test material form:
- other: Clear colourless liquid
- Details on test material:
- - Test Material : Octadecene
- CAS 27070-58-2
- Chemical name: C18 Isomerized Olefin
- Physical State/Appearance : Clear colourless liquid
- Purity : 94.1%
- Label : C18 Isomerised Olefin Lot 747273
- Batch Number : 747273
- Date Received : 03 March 2014
- Storage Conditions : Ambient temperature, in the dark and under nitrogen
- Expiry Date : 10 Feb 2016
Constituent 1
- Specific details on test material used for the study:
- - Test Material : Octadecene
- CAS 27070-58-2
- Chemical name: C18 Isomerized Olefin
– Physical State/Appearance : Clear colourless liquid
- Purity : 94.1%- Label : C18 Isomerised Olefin Lot 747273
– Batch Number : 747273- Date Received : 03 March 2014
- Storage Conditions : Ambient temperature, in the dark and under nitrogen
- Expiry Date : 10 Feb 2016
Octadecene used in this study was a typical production sample, according to the details included in the boundary composition in IUCLID section 1.2. Octadecene was chosen in the Higher Olefins category testing strategy because it represents a substance with high di-sub content (category range 0.3 – 94%) and high tri-sub content (category range 1 - 65%). Please see the testing strategy attached in section 13 for further details.
Test animals
- Species:
- rat
- Strain:
- other: Wistar Han™:RccHan™:WIST
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Harlan Laboratories U.K. Ltd., Oxon, UK
- Age at study initiation: six to eight weeks old
- Weight at study initiation: Males: 200 to 232g, Females: 141 to 175g
- Housing: The animals were housed in groups of three or four by sex in solid floor polypropylene cages with stainless steel mesh lids and softwood flake bedding
- Diet (e.g. ad libitum): A pelleted diet (Rodent 2014C Teklad Global Certified Diet, Harlan Laboratories U.K. Ltd., Oxon, UK - free access
- Water (e.g. ad libitum): free access
- Acclimation period: 9 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22 ± 3 °C
- Humidity (%): 50 ± 20%
- Air changes (per hr): 15
- Photoperiod (hrs dark / hrs light): 12 hr light/12 hr dark
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: arachis oil BP
- Details on oral exposure:
- The test item was administered daily, for ninety consecutive days, by gavage using a stainless steel cannula attached to a disposable plastic syringe. Control animals were treated in an identical manner with 4 mL/kg of Arachis oil BP.
The volume of test and control item administered to each animal was based on the most recent
scheduled body weight and was adjusted at weekly intervals. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- The test item was prepared in Arachis oil BP solution. The stability and homogeneity of the test item formulations were determined by Harlan Laboratories Ltd., Shardlow, UK, Analytical Services. The results of the analytical determination showed that the formulations were stable for at least 18 days. Formulations were prepared and stored at approximately 4 °C in the dark.
The results indicate that the prepared formulations were within 90% to 102% of the nominal concentration confirming the suitability and accuracy of the formulation procedure. - Duration of treatment / exposure:
- 90 days
- Frequency of treatment:
- daily
Doses / concentrationsopen allclose all
- Remarks:
- Doses / Concentrations:
0 mg/kg bw/day
Basis:
actual ingested
- Remarks:
- Doses / Concentrations:
100 mg/kg bw/day
Basis:
actual ingested
- Remarks:
- Doses / Concentrations:
300 mg/kg bw/day
Basis:
actual ingested
- Remarks:
- Doses / Concentrations:
1000 mg/kg bw/day
Basis:
actual ingested
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: The dose levels were selected based on a fourteen day dose range finding study in the rat (Harlan Study Number: 41403655). In this study, a high dosage of 1000 mg/kg bw/day was well tolerated, therefore, the dose levels 0 (Control), 100, 300 and 1000 mg/kg bw/day were selected for the OECD 408 study.
- The test item was administered daily, for ninety consecutive days, by gavage using a stainless steel cannula attached to a disposable plastic syringe. - Control animals were treated in an identical manner with 4 mL/kg of Arachis oil BP.
Examinations
- Observations and examinations performed and frequency:
- Clinical Observations:
- Signs of toxicity
- Ill-health or behavioural change immediately before dosing
Functional Observations:
- Prior to the start of treatment and at weekly intervals thereafter
Behavioural Assessment
- Functional Performance Tests: Motor Activity, Forelimb/Hindlimb Grip Strength
- Sensory Reactivity
Body Weight
- Individual body weights were recorded on Day 1 (prior to dosing), at weekly intervals thereafter and at terminal kill
Food Consumption
- Weekly intervals throughout the study
Water Consumption
- Daily by visual inspection of the water bottles
Ophthalmoscopic Examination
- Pre-treatment and before termination of treatment (during Week 12)
Laboratory Investigations
- End of the study
- Haematology
- Blood Chemistry - Sacrifice and pathology:
- Sacrifice: All animals were terminated by intravenous overdose of a suitable barbiturate agent followed by exsanguination.
Pathology
- Necropsy: all animals were subjected to a full external and internal examination.
- Organ Weights (Adrenals, Ovaries, Brain Spleen, Epididymides, Testes, Heart, Thymus, Kidneys, Uterus, Liver)
- Histopathology: Samples of selected tissues were removed from all animals and preserved.
- Tissues from all control and high dose group animals were examined microscopically. - Statistics:
- Where considered appropriate, quantitative data was subjected to statistical analysis to detect the significance of intergroup differences from control; statistical significance was achieved at a level of p<0.05. Statistical analysis was performed on the following parameters:
Grip Strength, Motor Activity, Body Weight Change, Hematology, Blood Chemistry, Absolute Organ Weights, Body Weight-Relative Organ Weights.
Data were analyzed using the decision tree from the Provantis TM Tables and Statistics Module as detailed as follows:
Where appropriate, data transformations were performed using the most suitable method. The homogeneity of variance from mean values was analyzed using Bartlett’s test. Intergroup variances were assessed using suitable ANOVA, or if required, ANCOVA with appropriate
covariates. Any transformed data were analyzed to find the lowest treatment level that showed a significant effect using the Williams Test for parametric data or the Shirley Test for nonparametric data.
If no dose response was found but the data shows non-homogeneity of means, the data were analysed by a stepwise Dunnett’s (parametric) or Steel (non-parametric) test to determine significant difference from the control group. Where the data were unsuitable for these analyses, pair-wise tests was performed using the Student t-test (parametric) or the MannWhitney U test (non-parametric). Probability values (p) are presented as follows:
p<0.01 **
p<0.05 *
p>0.05 (not significant)
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Treatment at 1000 mg/kg bw/day was associated with increased post-dosing salivation for both sexes. Similar increased post-dosing salivation was also observed for one male and four females at 300 mg/kg bw/day.
- Mortality:
- no mortality observed
- Description (incidence):
- There were no unscheduled deaths on the study.
- Body weight and weight changes:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There was no effect of treatment on body weight performance for either sex at 100, 300 or 1000 mg/kg bw/day.
Overall body weight gain for treated animals was slightly superior to control and the occasional statistically significant differences in body weight gain for treatedanimals were considered to reflect normal biological variation and were unrelated to treatment. - Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- There was no effect of treatment on food consumption for either sex at 100, 300 or 1000 mg/kg bw/day.
- Food efficiency:
- no effects observed
- Description (incidence and severity):
- There was no effect of treatment on food conversion efficiency for either sex at 100, 300 or 1000 mg/kg bw/day.
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Description (incidence and severity):
- There was no effect of treatment on water consumption for either sex at dosages of 100, 300 or 1000 mg/kg bw/day.
- Ophthalmological findings:
- no effects observed
- Description (incidence and severity):
- Ophthalmic examination of the eyes from rats receiving 1000 mg/kg bw/day did not indicate any effect of treatment.
- Haematological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There was considered to be no effect of treatment on hematology parameters for either sex at 100, 300 or 1000 mg/kg bw/day.
At all dosages, mean corpuscular hemoglobin concentration for both sexes was lower than control; with the exception of females at 100 mg/kg bw/day, all differences from control attained statistical significance. However, only individual values for two males at 100 mg/kg bw/day and one male at 300 mg/kg bw/day exceeded the historical control range, while this historical range was exceeded by the majority of control males. For females only one control female exceeded the historical control range and all individual values for treated females were within the historical control range.
For females at 1000 mg/kg bw/day, mean hemoglobin level were also statistically significantly lower than control; however only one individual value for these treated animals was below the historical control range while this historical range was exceeded by four control females. - Clinical biochemistry findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There was considered to be no effect of treatment on blood chemistry parameters for either sex at 100, 300 or 1000 mg/kg bw/day.
For males at 1000 mg/kg bw/day, higher albumin and calcium levels attained statistical significance when compared with control but all individual values were within the historical control range; additionally for albumin there was no accompanying statistically significant difference from control for total protein or albumin/globulin ratio. Lower bile acid levels for males at this dosage also attained statistical significance when compared with control. While
individual values for half of these treated animals exceeded the control range, the majority of control values also exceeded this historical range. These differences from control in blood parameters, in the absence of any histopathological correlates were considered to be incidental and unrelated to treatment.
Additionally, for females at 1000 mg/kg bw/day, lower urea and creatinine levels also attained statistical significance when compared with control but all individual values for treated animals were within the historical control range while approximately half of the control urea values exceeded this historical range. For females at all dosage levels, lower bile acid values attained statistical significance when compared to controls but there was no dose response relationship.
Higher inorganic phosphorus levels for females at 300 mg/kg bw/day and lower glucose levels for females at 100 mg/kg bw/day also attained statistical significance when compared with control but there were no similar findings at the high dosage of 1000 mg/kg bw/day.
Overall these differences in urea, bile acid, creatinine and glucose levels were considered to be incidental and unrelated to treatment. - Urinalysis findings:
- not examined
- Behaviour (functional findings):
- effects observed, non-treatment-related
- Description (incidence and severity):
- Behavioral Assessments:
Weekly assessment of the animals in a standard arena did not reveal any obvious adverse effects of treatment at dosages of 100, 300 or 1000 mg/kg bw/day.
Functional Performance Tests:
Assessment of functional performance using grip strength and motor activity did not indicate any obvious effects of treatment for either at dosages of 100, 300 or 1000 mg/kg bw/day.
For males, higher values for hind limb grip strength during the third testing occasion attained statistical significance at all dosages, when compared with controls. Additionally, fore limb grip strength for males at 300 mg/kg bw/day was also statistically significantly higher than control during the first testing occasion. Given the lack of any dosage relationship, these observed differences in performance from control were considered to reflect normal biological variation and were unrelated to treatment.
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Description (incidence and severity):
- There were no statistically significant differences from control in absolute and body weight relative organ weights for either sex at 100, 300 or 1000 mg/kg bw/day.
- Gross pathological findings:
- no effects observed
- Description (incidence and severity):
- Neither the type, incidence nor distribution of findings observed at terminal necropsy indicated any obvious effect of treatment 100, 300 or 1000 mg/kg bw/day.
- Neuropathological findings:
- not specified
- Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- Neither the type, incidence nor distribution of findings observed during microscopic examination of the tissues from animals that received 1000 mg/kg bw/day indicated any effect of treatment.
- Histopathological findings: neoplastic:
- not specified
- Other effects:
- not specified
- Details on results:
- Mortality
- No unscheduled death
Clinical Observations
- 1000 mg/kg bw/day: male and female rats showed increased salivation.
- 300 mg/kg bw/day: Increased salivation was observed in one male and four females. This effect is not considered related to the treatment.
- 100 mg/kg bw/day: no effects
Functional Observations
- Hind limb grip strength fore limb grip strength were observed in males treated with 300 mg/kg bw/day. The lack of dose-response relationship suggested
that these observations reflected normal biological variation and were unrelated to treatment.
- No treatment-related effects were observed in the behavioural and sensory reactivity parameters.
Body Weight
- There was no effect of treatment on body weight performance for either sex at 100, 300 or 1000 mg/kg bw/day.
Overall body weight gain for treated animals was slightly superior to control and the occasional statistically significant differences in body weight gain for treatedanimals were considered to reflect normal biological variation and were unrelated to treatment.
Food Consumption
- There was no effect of treatment on food consumption for either sex at 100, 300 or 1000 mg/kg bw/day.
Water Consumption
- There was no effect of treatment on water consumption for either sex at dosages of 100, 300 or 1000 mg/kg bw/day.
Ophthalmoscopic Examination
- Ophthalmic examination of the eyes from rats receiving 1000 mg/kg bw/day did not indicate any effect of treatment.
Haematological findings
-There was considered to be no effect of treatment on hematology parameters for either sex at 100, 300 or 1000 mg/kg bw/day.
Blood Chemistry
- There was considered to be no effect of treatment on blood chemistry parameters for either sex at 100, 300 or 1000 mg/kg bw/day.
Pathology
Necropsy and Histopatology
- Neither the type, incidence nor distribution of findings observed during microscopic examination of the tissues from animals that received 1000 mg/kg bw/day indicated any effect of treatment.
Organ Weights
- There were no statistically significant differences from control in absolute and body weight relative organ weights for either sex at 100, 300 or 1000 mg/kg bw/day.
Effect levels
- Dose descriptor:
- NOEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: No significant effects observed at 1000 mg/kg/day
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
Table 1. Group Mean Functional Performance Test Values |
|||||
Group |
|
Males |
Females |
||
Overall Activity |
Test 3 Hindlimb (g) |
Overall Activity |
Test 3 Hindlimb (g) |
||
Group 1 (0 – Control) |
Mean |
918.0 |
255.9 |
1062.2 |
323.9 |
S.D. |
284.8 |
45.3 |
264.3 |
81.5 |
|
N |
10 |
10 |
10 |
10 |
|
|
|||||
Group 2 (100 mg/Kg bw/day) |
Mean |
768.7 |
465.0 ** |
939.7 |
292.0 |
S.D. |
206.2 |
151.6 |
309.7 |
102.0 |
|
N |
10 |
10 |
10 |
10 |
|
|
|||||
Group 3 (300 mg/Kg bw/day) |
Mean |
943.9 |
495.3 ** |
975.0 |
278.3 |
S.D. |
335.0 |
166.8 |
255.0 |
108.6 |
|
N |
10 |
10 |
10 |
10 |
|
|
|||||
Group 4 (1000 mg/Kg bw/day) |
Mean |
808.1 |
313.7** |
1045.6 |
400.5 |
S.D. |
306.2 |
106.8 |
240.4 |
176.5 |
|
N |
10 |
10 |
10 |
10 |
|
General Footnote: Unit = Time (seconds) for Motor Activity Assessments
* Significantly different from control group p<0.05
** Significantly different from control group p<0.01
Table 2. Group Mean Hematological Values - Males |
|||
Group |
|
Hb (g/dL) |
MCHC (g/dL) |
Group 1 (0 – Control) |
Mean |
16.17 |
34.60 |
S.D. |
0.89 |
0.65 |
|
N |
10 |
10 |
|
|
|||
Group 2 (100 mg/Kg bw/day) |
Mean |
16.57 |
34.09* |
S.D. |
0.57 |
0.59 |
|
N |
10 |
10 |
|
|
|||
Group 3 (300 mg/Kg bw/day) |
Mean |
16.32 |
34.01* |
S.D. |
0.73 |
0.58 |
|
N |
10 |
10 |
|
|
|||
Group 4 (1000 mg/Kg bw/day) |
Mean |
16.30 |
33.56** |
S.D. |
0.61 |
0.39 |
|
N |
10 |
10 |
|
* Significantly different from control group p<0.05
** Significantly different from control group p<0.01
Table 3. Group Mean Blood Chemical Values - Males |
|
|||
Group |
|
Albumin (g/dL) |
Ca++ mmol/l |
Bile Acid µmol/l |
Group 1 (0 – Control) |
Mean |
3.76 |
2.680 |
21.16 |
S.D. |
0.24 |
0.083 |
10.50 |
|
N |
10 |
10 |
10 |
|
|
|
|||
Group 2 (100 mg/Kg bw/day) |
Mean |
3.93 |
2.720 |
14.40 |
S.D. |
0.18 |
0.149 |
9.37 |
|
N |
10 |
10 |
10 |
|
|
|
|||
Group 3 (300 mg/Kg bw/day) |
Mean |
3.86 |
2.731 |
15.22 |
S.D. |
0.21 |
0.115 |
9.42 |
|
N |
10 |
10 |
10 |
|
|
|
|||
Group 4 (1000 mg/Kg bw/day) |
Mean |
3.97* |
2.801* |
12.26* |
S.D. |
0.13 |
0.080 |
7.91 |
|
N |
10 |
10 |
10 |
|
* Significantly different from control group p<0.05
Table 4. Group Mean Hematological Values - Females |
|||
Group |
|
Hb (g/dL) |
MCHC (g/dL) |
Group 1 (0 – Control) |
Mean |
16.13 |
34.37 |
S.D. |
0.68 |
0.81 |
|
N |
10 |
10 |
|
|
|||
Group 2 (100 mg/Kg bw/day) |
Mean |
15.94 |
34.16 |
S.D. |
0.54 |
0.27 |
|
N |
10 |
10 |
|
|
|||
Group 3 (300 mg/Kg bw/day) |
Mean |
16.14 |
33.97* |
S.D. |
0.93 |
0.30 |
|
N |
10 |
10 |
|
|
|||
Group 4 (1000 mg/Kg bw/day) |
Mean |
14.94** |
33.89* |
S.D. |
1.42 |
0.34 |
|
N |
10 |
10 |
|
* Significantly different from control group p<0.05
** Significantly different from control group p<0.01
Table 5. Group Mean Blood Chemical Values - Females |
|
|
|
|
|||
Group |
|
Urea mg/dl |
Glucose mg/dl |
P mmol/l |
ALAT IU/l |
Creat mg/dl |
Bile Acid µmol/l |
Group 1 (0 – Control) |
Mean |
49.4 |
183.4 |
1.62 |
55.8 |
0.892 |
36.18 |
S.D. |
8.9 |
30.6 |
0.35 |
10.3 |
0.134 |
19.69 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
|
|
|
|
|
|
|||
Group 2 (100 mg/Kg bw/day) |
Mean |
47.6 |
152.2** |
1.55 |
63.5 |
0.852 |
15.20* |
S.D. |
7.8 |
14.4 |
0.27 |
21.6 |
0.071 |
14.89 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
|
|
|
|
|
|
|||
Group 3 (300 mg/Kg bw/day) |
Mean |
45.1 |
169.5 |
1.96* |
59.2 |
0.894 |
25.32* |
S.D. |
12.0 |
16.1 |
0.31 |
19.4 |
0.238 |
18.37 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
|
|
|
|
|
|
|||
Group 4 (1000 mg/Kg bw/day) |
Mean |
40.4* |
170.5 |
1.56 |
73.7* |
0.795* |
17.72* |
S.D. |
5.5 |
18.6 |
0.28 |
14.5 |
0.048 |
13.51 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
|
* Significantly different from control group p<0.05
** Significantly different from control group p<0.01
Table 6. Group Mean Organ Weights with Corresponding Relative (% of Body Weight) Organ Weights |
|||||||||
|
|
Males |
Females |
||||||
0 Control |
100 mg/Kg bw/day |
300 mg/Kg bw/day |
1000 mg/Kg bw/day |
0 Control |
100 mg/Kg bw/day |
300 mg/Kg bw/day |
1000 mg/Kg bw/day |
||
Kidneys |
Mean (g) |
2.12673 |
2.19061 |
2.26685 |
2.20039 |
1.40115 |
1.50356 |
1.42171 |
1.52647 |
S.D. |
0.38474 |
0.23642 |
0.28298 |
0.28953 |
0.14245 |
0.08800 |
0.10481 |
0.14570 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
|
|
|||||||||
Mean (%) |
0.541 |
0.520 |
0.558 |
0.528 |
0.578 |
0.604 |
0.569 |
0.615 |
|
S.D. |
0.047 |
0.039 |
0.047 |
0.033 |
0.045 |
0.028 |
0.034 |
0.042 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
|
|
|||||||||
Liver |
Mean (g) |
12.6118 |
13.6667 |
13.6800 |
13.0910 |
8.20024 |
8.40268 |
8.26177 |
8.60674 |
S.D. |
2.28005 |
1.53962 |
1.78418 |
2.96040 |
0.88450 |
0.86053 |
0.59297 |
1.01931 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
|
|
|||||||||
Mean (%) |
3.207 |
3.239 |
3.357 |
3.113 |
3.382 |
3.370 |
3.306 |
3.463 |
|
S.D. |
0.261 |
0.176 |
0.219 |
0.286 |
0.258 |
0.292 |
0.201 |
0.267 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
|
|
|||||||||
Spleen |
Mean (g) |
0.69673 |
0.80295 |
0.72930 |
0.76011 |
0.53533 |
0.57430 |
0.57771 |
0.61159 |
S.D. |
0.10764 |
0.10653 |
0.09619 |
0.13641 |
0.05239 |
0.06556 |
0.12066 |
0.14834 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
|
|
|||||||||
Mean (%) |
0.178 |
0.191 |
0.179 |
0.182 |
0.221 |
0.230 |
0.232 |
0.247 |
|
S.D. |
0.023 |
0.024 |
0.016 |
0.017 |
0.020 |
0.025 |
0.053 |
0.063 |
|
N |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
10 |
|
Table 7. Summary Incidence of Necropsy Findings - Males |
||||
|
Males |
|||
0 Control |
100 mg/Kg bw/day |
300 mg/Kg bw/day |
1000 mg/Kg bw/day |
|
Number of animals examined |
10 |
10 |
10 |
10 |
Adrenals |
|
|||
Submitted |
(10) |
(10) |
(10) |
(10) |
No Visible Lesions |
10 |
10 |
10 |
9 |
Damaged On Removal; right |
0 |
0 |
0 |
1 |
|
||||
Kidneys |
|
|||
Submitted |
(10) |
(10) |
(10) |
(10) |
No Visible Lesions |
10 |
9 |
10 |
10 |
Increased Pelvic Space; right |
0 |
1 |
0 |
0 |
Fluid Filled; right |
0 |
1 |
0 |
0 |
|
||||
Lungs (With Bronchi) |
|
|||
Submitted |
(10) |
(10) |
(10) |
(10) |
No Visible Lesions |
9 |
10 |
10 |
8 |
Discolouration; Red |
1 |
0 |
0 |
2 |
Table 8. Summary Incidence of Necropsy Findings - Females |
||||
|
Females |
|||
0 Control |
100 mg/Kg bw/day |
300 mg/Kg bw/day |
1000 mg/Kg bw/day |
|
Number of animals examined |
10 |
10 |
10 |
10 |
Brain (Including Cerebrum, Cerebellum And Pons) |
|
|||
Submitted |
(10) |
(10) |
(10) |
(10) |
No Visible Lesions |
9 |
10 |
10 |
10 |
Damaged On Removal; right |
1 |
0 |
0 |
0 |
|
||||
Lungs (With Bronchi) |
|
|||
Submitted |
(10) |
(10) |
(10) |
(10) |
No Visible Lesions |
6 |
9 |
9 |
9 |
Discolouration; red |
4 |
1 |
1 |
1 |
|
||||
Uterus (With Cervix) |
|
|||
Submitted |
(10) |
(10) |
(10) |
(10) |
No Visible Lesions |
10 |
10 |
9 |
10 |
Discolouration; Red |
0 |
0 |
1 |
0 |
Applicant's summary and conclusion
- Conclusions:
- Based on the results of this study, the No Observed Effect Level (NOEL) for systemic toxicity was considered to be 1000 mg/kg bw/day.
- Executive summary:
The daily oral gavage administration of Octadecene CAS 27070-58-2 to rats for a period of ninety consecutive days at dosages of 100, 300 or 1000 mg/kg bw/day was well tolerated and was not associated with any obvious signs of systemic toxicity for animals of either sex. At 1000 mg/kg bw/day and, to a much lesser extent, 300 mg/kg bw/day, treatment was associated with increased post-dosing salivation for both sexes but this was considered to reflect distaste or slight irritancy of the dosing formulations rather than any systemic effect of treatment. There were no effects of treatment indicated by body weight performance, food and water consumption, food conversion efficiency, functional observations or ophthalmic examinations.
Intergroup differences for hematology and blood chemistry parameters did not indicate any clear effect of treatment and the few mean values that attained statistical significance when compared with control were considered to be incidental and of no toxicological significance. There were no statistically significant differences apparent for organ weights and neither macroscopic nor subsequent microscopic examination of tissues revealed any treatment related effects.
Based on the results of this study, the No Observed Effect Level (NOEL) for systemic toxicity was considered to be 1000 mg/kg bw/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
